Adherence and UtilisationAdherence to nebulised antibiotics in cystic fibrosis
Introduction
Cystic fibrosis (CF) is a life-threatening hereditary multi-system disease predominantly affecting the pancreas and lungs. Advances in treatment have led to significant improvements in prognosis though this depends crucially upon adherence to treatment.
Non-adherence is a major problem in chronic illness, with rates of adherence noted between 30% and 70% [1]. Unsurprisingly, the demands of the complex treatment regimen in CF are associated with poor adherence [2].
One major confound in this literature is that definitions of non-adherence and the method of measurement often differ between investigators [3]. Self-report is often unreliable [4], as are methods such as counting pills [5]. Biochemical methods such as testing urine are more objective, but have been criticised for potential inaccuracies [5].
In CF, the treatment regimen has several components. Adherence is high to oral and intravenous medication (80–95%) [2], but low to nebulised therapies such as prophylactic antibiotics (65–80%) [6].
A major advance in measuring adherence to nebuliser use has been memory microchips concealed in the device. Research using these chips shows average adherence to nebulisers in CF ranges from 57% over the long-term [7] to 86% during a 7-day trial [8]. One complicating issue, however, is the ability of the patient to use the device effectively. Adaptive aerosol delivery (AAD) systems, such as the Prodose™ are breath activated and programmed to deliver a pre-set dose of medication, giving feedback to the patient and signalling audibly when that dose is complete [9], [10]. Significantly more complete doses are taken with the AAD system when compared to conventional nebulisers [11]. It is also easier to use: nebulisation time for AAD devices is reported to be significantly less than for conventional nebulisers [12] and patients using the device have reported that they found it better to use than their previous nebuliser [13].
These new devices therefore offer the possibility that some of the practical barriers to achieve good adherence such as time needed and ease of use may be reduced. The devices still require the patient to initiate treatment, and therefore afford the opportunity for accurate measurement of adherence.
This study aimed to assess the adherence of CF patients to nebulised antibiotics utilising an accurate, objective method.
Section snippets
Participants
Participants were all over 18 years of age with a diagnosis of CF. 101 adult patients attending a regional CF clinic were prescribed aerosolised colistin. Fifty-four (53.4%) were ineligible for various reasons: participation in another trial (n = 15); undergoing post-transplant or eradication therapy (n = 14); unable to be contacted (n = 13); too ill (n = 7); trying to conceive or pregnant (n = 3); substance user (n = 1), in prison (n = 1). Forty-seven patients were invited to participate. Six declined and
Results
The mean age of participants was 24.6 years (S.D. 5.3). Twenty (52.6%) of the sample were male. Most were single (n = 22, 61.1%), fifteen (39.4%) were married or co-habiting and one divorced. Eighteen participants (47.4%) were in full or part-time employment, fifteen (39.5%) unemployed or receiving invalidity support and five (13.1%) were students. Participants were white European (n = 34, 89.56%) or of Asian (India/Pakistan) origin (n = 4, 10.5%). Patients had been using a nebuliser for a mean number
Discussion
There are two important findings in this study. First, that there was great individual variation in rates of adherence in this sample of CF patients, with adherence generally being low. On average, participants used their nebuliser approximately half of the prescribed times. This is similar to the findings of Laurans et al. [16] who found patients were using their expectorants 53% of the times prescribed.
The second finding is that different definitions of adherence produced different results.
Acknowledgements
The authors would like to thank Richard Marsden and Alex Black at Profile Therapeutics (Respironics) for their support of this study, and for the provision of the Prodose nebulisers.
References (19)
- et al.
Home nebulised therapy for patients with COPD: patient compliance with treatment and its relationship to quality of life
Chest
(1997) - et al.
Quality of life in cystic fibrosis; the importance of disease severity and gender
J Cyst Fibros
(2003) - et al.
Self management of cystic fibrosis: a structural model for educational and behavioural variables
Soc Sci Med
(1994) - et al.
Treatment adherence: terminology, incidence and conceptualisation
- et al.
Compliance with treatment in adult patients with cystic fibrosis
Thorax
(1996) - World Health Organisation adherence for long-term therapies: evidence for action. Switzerland: WHO; 2003....
- et al.
Determinants of adherence in adults with cystic fibrosis
Thorax
(2002) - et al.
Methodological and conceptual issues in adherence
- et al.
Treatment compliance in adults with cystic fibrosis
Thorax
(1994)